Abstract
Zymeworks has signed its first major deal, a US$187 M global licensing agreement with Merck & Co. to develop and commercialise bispecific antibodies generated through use of its proprietary Azymetric™ platform against two targets in the areas of oncology and autoimmune disease. Merck will gain exclusive worldwide commercialisation rights to products derived from the collaboration. The deal is part of Merck’s strategy to advance the development of biologics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.